Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Princess Maxima Center for Pediatric Oncology
Fondazione Italiana Linfomi - ETS
Sorrento Therapeutics, Inc.
SecuraBio
Incyte Corporation
Novartis
University College, London
Children's Hospital Medical Center, Cincinnati
University of Michigan Rogel Cancer Center
Royal Marsden NHS Foundation Trust
CTI BioPharma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Jazz Pharmaceuticals
Yale University
M.D. Anderson Cancer Center
AstraZeneca
University of Alabama at Birmingham
Molecular Templates, Inc.
AbbVie
Children's Oncology Group
AbbVie
Mayo Clinic
La Jolla Pharmaceutical Company
M.D. Anderson Cancer Center
Enzon Pharmaceuticals, Inc.
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Nevada Cancer Institute